GET THE FULL COMPANY
ANALYSIS BUNDLE FOR
Edgewise Therapeutics
Who owns Edgewise Therapeutics?
Edgewise Therapeutics drew strong investor interest at its March 2021 IPO, raising about $176,000,000 and anchoring a capital structure dominated by life‑science venture firms and institutional investors. Ownership concentration signals a focused push toward clinical milestones for therapies like sevasemten.
Founded in 2017 in Boulder, Colorado, the company transitioned from tight founder and venture ownership to public institutional control, with market cap near $1.8–2.1B in early 2025; major shareholders shape governance and commercial strategy. See Edgewise Therapeutics Porter's Five Forces Analysis.
Who Founded Edgewise Therapeutics?
Founders and early ownership at Edgewise Therapeutics combined scientific leadership and institutional capital: Kevin Koch, Ph.D., Alan Russell, Ph.D., and Peter Thompson, M.D. formed the founding team in 2017 with OrbiMed providing the initial seed.
Founding team
Kevin Koch (CEO), Alan Russell (CSO) and Peter Thompson (OrbiMed partner) co-founded the company in 2017.
Initial funding
OrbiMed provided approximately $1.2 million in seed capital at formation to establish operations.
Series A
In 2019 a $50 million Series A led by OrbiMed and Novo Holdings materially diluted founder stakes to fund EDG-5506 clinical entry.
Series B
A $95 million Series B in 2020 brought investors such as Viking Global and Venrock, further shifting ownership toward institutional backers.
Founder vesting
Founder equity used standard four-year vesting schedules to align long-term incentives with clinical milestones and retain management continuity.
Shareholder protections
Early agreements included buy-sell clauses to prevent fragmented ownership before a public exit and to protect governance stability.
The board structure granted primary venture backers oversight while preserving scientific founders' operational control to pursue small-molecule discovery; see further corporate context in Mission, Vision & Core Values of Edgewise Therapeutics.
Ownership snapshot
Early ownership shifted from founder-majority at incorporation to institution-weighted after Series A/B fundraising rounds.
- Seed: OrbiMed ~$1.2M (2017)
- Series A: $50M (2019) — OrbiMed, Novo Holdings lead
- Series B: $95M (2020) — Viking Global, Venrock join
- Founder vesting: four-year schedules; buy-sell clauses included
How Has Edgewise Therapeutics’s Ownership Changed Over Time?
Key events reshaping Edgewise Therapeutics ownership include its Nasdaq IPO on March 26, 2021, follow-on offerings including a $240,000,000 capital raise in early 2024, and progressive institutionalization of the shareholder base driving a cash runway into 2027.
| Event | Impact on Ownership |
|---|---|
| IPO — March 26, 2021 (11,000,000 shares at $16.00) | Transition from venture-backed private company to public equity ownership |
| Follow-on offerings (incl. early 2024 raise) | Diversified shareholders; reduced founder/insider stake; extended cash runway |
| Institutional accumulation through 2024–Q1 2025 | Institutions hold ~92% of outstanding shares; concentrated biotech-focused investors |
As of Q1 2025 the ownership profile shows major institutional control, concentrated among specialist investors and reduced insider percentage.
Major stakeholders and stakes — Q1 2025
Institutional investors dominate, while insiders retain a meaningful but diluted position; strategic influence aligns with biotech expertise.
- Largest holder: OrbiMed Advisors — approx. 14.5%
- Viking Global Investors — approx. 9.8%
- Cormorant Asset Management — approx. 7.2%
- Janus Henderson Group — approx. 5.5%
- Insiders (founders/executives) — approx. 4.2%
These ownership concentrations indicate that 'smart money' institutional investors largely guide corporate strategy, regulatory positioning, and board oversight; see further context in Growth Strategy of Edgewise Therapeutics.
Who Sits on Edgewise Therapeutics’s Board?
The current Board of Directors at Edgewise Therapeutics comprises eight members blending scientific leadership and financial expertise; Kevin Koch serves as CEO and Director, and Peter Thompson of OrbiMed holds a board seat reflecting significant institutional ownership.
| Director | Affiliation | Role / Expertise |
|---|---|---|
| Kevin Koch | Executive | CEO; operational leadership in biotech |
| Peter Thompson | OrbiMed (institutional investor) | Investor representation; strategic oversight |
| Viking Global Representative | Viking Global (institutional investor) | Corporate governance; capital markets |
| Independent Director A | Industry veteran | Pharmaceutical commercialization |
| Independent Director B | Former biopharma executive | Regulatory and launch experience |
| Venture Community Representative | VC investor | Early-stage development strategy |
| Scientific Director | Research leader | Clinical and translational science |
| Finance Director | Capital markets specialist | Financial oversight and audit |
Edgewise uses a single-class common stock structure—one share, one vote—so voting power aligns directly with equity stakes; major holders such as OrbiMed and Viking Global therefore exert influence proportional to their ownership, affecting board elections and major actions.
Board Composition and Voting Dynamics
The board of eight balances investors and independents; institutional ownership concentration gives top shareholders significant sway, while management maintains daily control through the CEO-director role.
- Single-class share structure: one share = one vote
- Top shareholders (OrbiMed, Viking Global) hold largest voting blocs
- As of 2025, institutional ownership exceeded 60% of outstanding common stock
- Clean capital structure maintained to support potential M&A and licensing discussions
Concentrated institutional ownership has kept proxy contests minimal through early 2025; a shift among the top five shareholders could trigger rapid governance changes, given proportional voting under the company’s corporate structure—see further context on funding and investors in Revenue Streams & Business Model of Edgewise Therapeutics.
What Recent Changes Have Shaped Edgewise Therapeutics’s Ownership Landscape?
In the past 24 months Edgewise Therapeutics ownership has shifted toward institutional consolidation as the company advanced its Grand Canyon and Canyon Phase 2/3 programs; larger healthcare-dedicated funds and new passive index holders materially increased positions, reducing float volatility while raising governance expectations.
| Holder Type | Notable Participants | Position (approx.) |
|---|---|---|
| Active healthcare funds | Dedicated life-science investors and biotech crossover funds | ~32% combined |
| Large passive managers | BlackRock; Vanguard | 8.4% combined |
| Insiders & executives | Founders, CEO, senior management | Small steady holdings; modest sales in 2024–2025 |
Early 2025 saw a major secondary offering with high participation from existing holders; market-cap growth led to index inclusion in 2024–2025, attracting passive investors and increasing scrutiny on ESG and governance metrics.
Institutional consolidation
Concentration rose as healthcare-dedicated funds expanded stakes while passive index funds entered after market-cap thresholds were met.
Secondary offering, 2025
High participation from incumbents signaled confidence ahead of key 2025–2026 clinical readouts for sevasemten in muscular dystrophy programs.
Insider activity
Filings show steady, limited insider selling typical for mid-cap biotech vesting schedules; core leadership remains intact with added global launch advisors.
Acquisition prospects
Analysts view the company as an acquisition target for large-cap pharmas seeking rare-disease assets; a >50% reduction in muscle-damage markers from sevasemten would materially increase buyout likelihood.
For ownership history and details on corporate structure and investor lists, see Brief History of Edgewise Therapeutics
- What is Brief History of Edgewise Therapeutics Company?
- What is Competitive Landscape of Edgewise Therapeutics Company?
- What is Growth Strategy and Future Prospects of Edgewise Therapeutics Company?
- How Does Edgewise Therapeutics Company Work?
- What is Sales and Marketing Strategy of Edgewise Therapeutics Company?
- What are Mission Vision & Core Values of Edgewise Therapeutics Company?
- What is Customer Demographics and Target Market of Edgewise Therapeutics Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.